Nov 2021 $35 M No. 8 $10 to $50 million 16
Regulus Therapeutics Inc.: Raise no. 8, Nov 2021 × Investors in this round 16 investors had bought by the notice of Dec 6, 2021: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $35 M of $35 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,077,499
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christopher Aker · Executive Officer Cris Calsada · Executive Officer Denis Drygin · Executive Officer Joseph Hagan · Executive Officer, Director Alice S. Huang · Director David Baltimore · Director Hugh H. Rosen · Director Jake R. Nunn · Director Kathryn J. Collier · Director Pascale H. Witz · Director Simos H. Simeonidis · Director Stelios Papadopoulos · Director William H. Rastetter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H. C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, IL, MD, NY, PA, TX SVB Leerink LLC (CRD 39011) · Boston, Massachusetts Sold in CA, IL, MD, NY, PA, TX Signed by Christopher Aker, Sr. VP and General Counsel. Source: SEC Form D, newest notice filed Dec 6, 2021. Read the notice at the SEC .
equity SEC Dec 2020 $19 M No. 7 $10 to $50 million 18
Regulus Therapeutics Inc.: Raise no. 7, Dec 2020 × Investors in this round 18 investors had bought by the notice of Dec 17, 2020: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $19 M of $35 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,066,067
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christopher Aker · Executive Officer Cris Calsada · Executive Officer Denis Drygin · Executive Officer Joseph Hagan · Executive Officer, Director David Baltimore · Director Hugh H. Rosen · Director Jake R. Nunn · Director Kathryn J. Collier · Director Pascale H. Witz · Director Simos H. Simeonidis · Director Stelios Papadopoulos · Director William H. Rastetter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H. C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, CO, CT, MD, NY, OH, TX Remarks in the notice On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”Signed by Christopher Aker, Sr. VP and General Counsel. Source: SEC Form D, newest notice filed Dec 17, 2020. Read the notice at the SEC .
equity, options SEC May 2019 $17 M No. 6 $10 to $50 million 21
Regulus Therapeutics Inc.: Raise no. 6, May 2019 × Investors in this round 21 investors had bought by the notice of May 14, 2019: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $17 M of $79 M offered; $63 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,301,322
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christopher R. Aker · Executive Officer Daniel R. Chevallard · Executive Officer Joseph P. Hagan · Executive Officer, Director David R. Baltimore · Director Hugh H. Rosen · Director Kathryn L. Collier · Director Pascale H. Witz · Director Stelios R. Papadopoulos · Director William H. Rastetter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright Co. (CRD 375) · New York, New York Sold in CA, CT, MA, MD, NY Remarks in the notice On fees: “"""Sales Commissions"" includes amounts payable by the Issuer for both the initial closing and the milestone closing."”On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”Signed by Christopher Aker, Sr. VP and General Counsel. Source: SEC Form D, newest notice filed May 14, 2019. Read the notice at the SEC .
equity, options SEC Feb 2014 $10 M No. 5 $10 to $50 million 1
Regulus Therapeutics Inc.: Raise no. 5, Feb 2014 × Investors in this round 1 investor had bought by the notice of Feb 6, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kleanthis Xanthopoulos · Executive Officer, Director Neil Lynne Gibson · Executive Officer B. Lynne Parshall · Director Bruce L.A. Carter · Director David Baltimore · Director Douglas E. Williams · Director John H. Maraganore · Director Mark G. Foletta · Director Stelios H. Papadopoulos · Director William H. Rastetter · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher Aker, Corp. Secretary. Source: SEC Form D, newest notice filed Feb 6, 2014. Read the notice at the SEC .
equity SEC Oct 2012 $25 M No. 4 $10 to $50 million 1
Regulus Therapeutics Inc.: Raise no. 4, Oct 2012 × Investors in this round 1 investor had bought by the notice of Oct 23, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $25 M of $25 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Garry Lynne Menzel · Executive Officer Kleanthis Xanthopoulos · Executive Officer, Director Neil Lynne Gibson · Executive Officer B. Lynne Parshall · Director Barry E. Greene · Director Bruce L.A. Carter · Director David Baltimore · Director John E. Maraganore · Director Stanley Crooke · Director Stelios E. Papadopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher Aker, Corp. Secretary. Source: SEC Form D, newest notice filed Oct 23, 2012. Read the notice at the SEC .
equity SEC Aug 2012 $5 M No. 3 $2 to $10 million 1
Regulus Therapeutics Inc.: Raise no. 3, Aug 2012 × Investors in this round 1 investor had bought by the notice of Oct 23, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Garry Lynne Menzel · Executive Officer Kleanthis Xanthopoulos · Executive Officer, Director Neil Lynne Gibson · Executive Officer B. Lynne Parshall · Director Barry E. Greene · Director Bruce L.A. Carter · Director David Baltimore · Director John E. Maraganore · Director Stanley Crooke · Director Stelios E. Papadopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Christopher Aker, Corp. Secretary. Source: SEC Form D, newest notice filed Oct 23, 2012. Read the notice at the SEC .
debt, options SEC Oct 2010 $10 M No. 2 $10 to $50 million 1
Regulus Therapeutics Inc.: Raise no. 2, Oct 2010 × Investors in this round 1 investor had bought by the notice of Nov 15, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Garry Lynne Menzel · Executive Officer Grantland Lynne Bryce · Executive Officer Kleanthis Xanthopoulos · Executive Officer, Director B. Lynne Parshall · Director Barry E. Greene · Director David Baltimore · Director John E. Maraganore · Director Stanley Crooke · Director Stelios E. Papadopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Grantland Bryce, Corp. Secretary. Source: SEC Form D, newest notice filed Nov 15, 2010. Read the notice at the SEC .
equity SEC Mar 2009 $20 M No. 1 $10 to $50 million 2
Regulus Therapeutics Inc.: Raise no. 1, Mar 2009 × Investors in this round 2 investors had bought by the notice of Nov 15, 2010: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Garry Lynne Menzel · Executive Officer Grantland Lynne Bryce · Executive Officer Kleanthis Xanthopoulos · Executive Officer, Director B. Lynne Parshall · Director Barry E. Greene · Director David Baltimore · Director John E. Maraganore · Director Stanley Crooke · Director Stelios E. Papadopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Grantland Bryce, Corp. Secretary. Source: SEC Form D, newest notice filed Nov 15, 2010. Read the notice at the SEC .
equity SEC Jan 2009 $30 M Issued in a merger or acquisition $10 to $50 million 2
Regulus Therapeutics Inc.: Private sale, Jan 2009 × Investors in this round 2 investors had bought by the notice of Nov 15, 2010: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Garry Lynne Menzel · Executive Officer Grantland Lynne Bryce · Executive Officer Kleanthis Xanthopoulos · Executive Officer, Director B. Lynne Parshall · Director Barry E. Greene · Director David Baltimore · Director John E. Maraganore · Director Stanley Crooke · Director Stelios E. Papadopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents the value of certain shares of the Issuer's Series A Preferred Stock issued in exchange for LLC membership interests in connection with the conversion of the Issuer from an LLC into a corporation under Delaware law.”On a merger: “The reported transaction includes the exchange of LLC membership interests for shares of Series A Preferred Stock of the Issuer in connection with the conversion of the Issuer from an LLC into a corporation under Delaware law”Signed by Grantland Bryce, Corp. Secretary. Source: SEC Form D, newest notice filed Nov 15, 2010. Read the notice at the SEC .
equity SEC